Comparison of low-dose rofecoxib versus 1000 mg naproxen in patients with osteoarthritis

References

• Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Griffin MR, et al. Guidelines for the medical management of osteoarthritis: Part I. osteoarthritis of the hip. Arthritis Rheum 1995;38:1535–40.
   PubMed Web of Science ®Google Scholar
• Towheed TE, Hochberg MC. A systematic review of randomized controlled trials of pharmacological therapy in osteoarthritis of the hip. J Rheumatol 1997;24:349–57.
   PubMed Web of Science ®Google Scholar
• Rehman Q, Lane NE. Getting control of osteoarthritis pain. Rheum Dis Clin North Am 1999;106:1–10.
   Google Scholar
• FitzGerald GA, Patrono C. The human pharmacology of the coxibs: inhibitors of cyclooxygenase-2. In: Vane JR, Botting RM, eds. Therapeutic roles of selective COX-2 inhibitors. London: William Harvey Press, 2001:442–60.
   Google Scholar
• Lefkowith JB, Verburg KM, Geis GS. Clinical experience with celecoxib: a cyclooxygenase-2 specific inhibitor. In: Vane JR, Botting RM, editors. Therapeutic roles of selective COX-2 inhibitors. London: William Harvey Press, 2001:461–81.
   Google Scholar
• Morrison B, Simon TJ, DeTora L, Sperling R. Rofecoxib: clinical studies. In: Vane JR, Botting RM, editors. Ther-apeutic roles of selective COX-2 inhibitors. London: William Harvey Press, 2001:541–59.
   Google Scholar
• Saag K, Van der Heijde D, Fisher C, Samara A, DeTora L, Bolognese J. Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs — A 6-week and a 1-year trial in patients with osteoarthritis. Arch Fam Med 2000;9:1124–34.
   PubMedGoogle Scholar
• Schnitzer TJ, Truitt K, Fleischmann R, Dalgin P, Block J, Zeng Q, et al. The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Clin Ther 1999;21:168 8–702.
   Google Scholar
• Acevedo E, Castarieda 0, Ugaz M, Beaulieu AD, Pons-Estel B, Caeiro F, et al. Tolerability profiles of rofecoxib (VIOXX(9) and Arthrotec(n> Scand J Rheumatol 2001; 30:19–24.
   PubMed Web of Science ®Google Scholar
• Bombardier C, LaMe L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheuma-toid arthritis. N Engl J Med 2000;343:1520–8.
   Google Scholar
• Langman MJ, Jensen DM, Watson DJ, Harper ES, Zhoa PL, Quan H, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDS. JAMA 1999;282:192 9–33.
   PubMedGoogle Scholar
• Watson DJ, Harper SE, Zhao P-L, Quan H, Bolognese JA, Simon TJ. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch Intern Med 2000;160: 2998–3003.
   Google Scholar
• Physicians' Desk Reference EC-NAPROSYN(m(naproxen) delayed-release tablets; NAPROSYN(n) (naproxen) tablets; ANAPROVHIANAPROX(mDS (naproxen sodium) tablets; NAPROSYNcm(naproxen) suspension [Package Insert]. 54 ed. Montvale (NJ): Medical Economics Company, Inc., 2000:263 1-4. 1999.
   Google Scholar
• Bellamy N. WOMAC osteoarthritis index: a user's guide. In: Anonymous Western Ontario and McMaster Universities, 1995.
   Google Scholar
• Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1999; 15:1833–40.
   Google Scholar
• Ehrich EW, Schnitzer TJ, Malwain H, Levy R, Wolfe F, Weisman M, et al. Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. J Rheumatol 1999; 26:2438–47.
   PubMed Web of Science ®Google Scholar
• Altman R, Brandt K, Hochberg M, Moskowitz R, Bellamy N, Bloch DA, et al. Design and conduct of clinical trials in patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society. Osteoarthritis Cartilage 1996;4:217–43.
   PubMed Web of Science ®Google Scholar
• Dougados M, LeClaire P, Van der Heijdet D, Bloch DA, Bellamy N, Altman RD. Response criteria for clinical trials on osteoarthritis of the knee and hip: a report of the osteoarthritis research society international standing commit-tee for clinical trials response criteria initiative. Osteoarthritis Cartilage 2000;8:395–403 .
   PubMed Web of Science ®Google Scholar
• Bolognese J, Ehrich E, Schnitzer T, Zeng Q. Precision of composite measures of osteoarthritis efficacy compared with that of individual endpoints. Arthritis Rheum 1998; 41.
   PubMed Web of Science ®Google Scholar
• Ehrich EW, Davies GM, Watson DJ, Bolognese JA, Seidenberg BC, Bellamy N. Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities Osteoarthritis index questionnaire and global assessments in patients with osteoarthritis. J Rheumatol 2000;27:263 5–2641.
   Google Scholar
• Geba GP, Weaver AL, Polis AB, Dixon ME, Schnitzer TJ. Efficacy of Rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. JAMA 2002;287:6 4–71.
   Google Scholar
• Leung AT, Malmstrom K, Gallacher AE, Sarembock B, Poor G, Beaulieu A, et al. Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: a randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trail. Curr Med Res Opin 2002;18:49–58.
   PubMed Web of Science ®Google Scholar
• Morrison BW, Fricke J, Brown J, Yuan W, Kotey P, Mehlisch D. The optimal analgesic dose of rofecoxib: overview of six randomized controlled trials. JAMA 2000;131:172 9–37.
   Google Scholar
• Bensen W, Weaver A, Espinoza L, Riley W, Paperiello B, Hamilton DPR. Valdecoxib, a new COX-2 specific inhibitor, is effective in treating the signs and symptoms of rheumatoid arthritis. Arthritis Rheum 2001;44:5369 Abstract.
   Google Scholar
• Clemett D, Goa KL. Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs 2000;59:95 7–80.
   PubMed Web of Science ®Google Scholar
• Simon LS, Weaver AL, Graham DY, Kivitz A, Lipsky PE, Hubbard RC, et al. Anti-inflammatory and upper gastro-intestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999;282:192 1–8.
   Google Scholar
• Brater DC, Harris C, Redfem JS, Gertz BJ. Renal Effects of COX-2-selective inhibitors. Am J Nephrol 2001;21:1–15.
   PubMed Web of Science ®Google Scholar
• Whelton A, Fort JG, Puma JA, Normandin D, Bello AE, Verburg KM. Cyclooxygenase-2-specific inhibitors and cardi-orenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001;8:85–95.
   PubMedGoogle Scholar
• Reicin AS, Shapiro D, Sperling RS, Barr E, Yu Q. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). Am J Cardiol 2002;89:204–9.
   Google Scholar
• Gertz BJ, Krupa D, Bolognese JA, Sperling RS, Reicin A. A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents. Curr Med Res Opin 2002;18:82–91.
   Google Scholar